Description of the data source, numerator, denominator, survey questions, and other relevant details about the national estimate.
Number of persons aged 13 to 15 years receiving at least 1 dose of a tetanus-diphtheria-acelluar pertussis (Tdap) booster vaccine
Number of persons aged 13 to 15 years
NIS-Teen collects vaccination information for adolescents aged 13–17 years in the 50 states, the District of Columbia, selected areas, and the U.S. Virgin Islands, using a random-digit–dialed sample of landline and, starting in 2011, cellular telephone numbers. Parent/guardian respondents provide vaccination and sociodemographic information on adolescents in their care. After the parent/guardian grants permission to contact their child's vaccination provider, a questionnaire is mailed to that provider to obtain a vaccination history from the medical record. Data for this measure were restricted to adolescents aged 13–15 and weighted to represent the population of adolescents age 13-15, with adjustments for households with multiple telephone lines and mixed telephone use (landline and cellular), household nonresponse, and exclusion of households without telephone service.
In 2006, the Advisory Committee on Immunization Practices (ACIP) recommended that 1) adolescents aged 11--18 years should receive a single dose of Tdap for booster immunization if they had completed the recommended childhood DTP/DTaP vaccination series and have not received Td or Tdap; 2) adolescents aged 11--18 years who received Td, but not Tdap, are encouraged to receive a single dose of Tdap to provide protection against pertussis if they have completed the recommended childhood DTP/DTaP vaccination series; and 3) vaccine providers should administer Tdap and tetravalent meningococcal conjugate vaccine (tracked in Healthy People objective to adolescents aged 11--18 years during the same visit if both vaccines are indicated and available. In 2010, ACIP approved the following additional recommendations: 1) use of Tdap regardless of interval since the last tetanus- or diphtheria-toxoid containing vaccine, 2) use of Tdap in certain adults aged 65 years and older, and 3) use of Tdap in undervaccinated children aged 7 through 10 years.
This measure tracks the proportion of adolescents aged 13–15 years receiving at least 1 dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years.
Additional resources about the objective.
This hyperlink will direct you to a non-governmental Website or application.
The appearance of external hyperlinks does not constitute endorsement by the United
States Department of Health & Human Services (HHS) of the hyperlinked Website
or application, or the information, products or services contained therein. Such
hyperlinks are provided consistent with the intended purpose of this HHS Website.
Visitors to the hyperlinked Website or application will be subject to the Website
or application's privacy policies. These practices may be different than those of
this HHS Website.
You will be redirected to: link